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and W. J. E. Tissingb,d
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ABSTRACT
Background: Recent findings by Tang et al. (2020) show dietary restriction (30%, 2 weeks) prevents 
methotrexate-induced mortality by modulation of the microbiota, specifically the expansion of 
Lactobacillus. While fundamentally insightful, upscaling this schedule is a major obstacle to clinical 
uptake. Here, we evaluate a safe and clinically achievable schedule of pre-therapy fasting for 48 h on 
microbiota composition, body composition and intestinal proliferation, and assess its impact on the 
severity of methotrexate-induced gastrointestinal mucositis using a validated preclinical rat model.
Methods: Age- and weight-matched male Wistar rats were treated with a sublethal dose of 45 mg/ 
kg methotrexate with or without pre-therapy fasting. The impact of acute fasting on epithelial 
proliferation, body composition and the microbiota was assessed using plasma citrulline, Ki67 
immunohistochemistry, miniSpec and 16S rRNA sequencing. The severity of gastrointestinal muco-
sitis was evaluated using plasma citrulline and body weight.
Results: Whilst pre-therapy fasting slowed epithelial proliferation and increased microbial diversity 
and richness, it also induced significant weight loss and was unable to attenuate the severity of 
mucositis in both age- and weight-matched groups. In contrast to Tang et al., we saw no expansion 
of Lactobacillus following acute fasting.
Conclusions: Our findings suggest that the beneficial effects of acute fasting are masked by the 
detrimental effects on body weight and composition and lacking influence on Lactobacillus. Future 
studies should consider alternative fasting schedules or aim to induce comparable microbial and 
mucosal manipulation without compromising body composition using clinically feasible methods 
of dietary or microbial intervention.
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Methotrexate (MTX) is a dihydrofolate reductase 
inhibitor capable of inducing cell cycle arrest and 
irreversible DNA damage in highly proliferative 
malignant cells.1 While a common chemotherapeu-
tic agent used for the treatment of acute leukemia 
and a variety of solid tumors, its use is limited due 
to various dose-limiting toxicities, namely bone 
marrow suppression and mucositis.2
Mucositis affecting the gastrointestinal tract (GI- 
M) is estimated to occur in 60–100% of patients, with 
severe, potentially lethal symptoms requiring inten-
sive supportive care and prompting dose reductions 
or treatment discontinuation.3 As such, GI-M has 
profound impacts on the likelihood of remission, the 
psychosocial wellbeing of the patient and is asso-
ciated with a profound economic burden.4,5 
Despite the clear need, there remains no gold stan-
dard method to prevent MTX-induced mucositis.6
The most recent advance in our understanding of 
MTX-induced mucositis has been the impact of the 
microbiota,7,8 in particular the microbial composition 
at the time of MTX administration. Preliminary evi-
dence from our laboratory shows that antibiotic- 
induced disruption of the microbiota worsens MTX- 
induced mucositis, increasing MTX-mortality and 
impairing mucosal recovery. These results align with 
existing preclinical findings9 and clinical risk factors, 
with antibiotic use prior to chemotherapy associated 
with increased GI-M severity.10 Similarly, while pro-
biotics have shown some benefits in mitigating the 
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severity of MTX associated GI-M,11 translational suc-
cess is variable.12 These findings have prompted an 
enthusiastic investigation of how the microbiota can 
be best modulated to improve MTX outcomes.
We read with interest the recent work by Tang 
et al., (2020) demonstrating that dietary restriction 
(DR; 30%) protects against MTX-induced mortality 
via modulation of the microbiota.9 While fundamen-
tally insightful, these findings are translationally 
challenging, with long-term DR unlikely to be feasi-
ble in most oncology settings. This is particularly 
pertinent when considering the DR schedule 
employed by Tang and colleagues which com-
menced 2 weeks prior to MTX administration. 
When scaling up to human equivalent schedules, 
this would require long-term DR to be implemented 
thus impacting the ability to deliver first-line therapy 
in a timely fashion. Here, we show comparable 
microbial modulation and slowed epithelial prolif-
eration following a clinically feasible 48 h fasting and 
evaluated its impact on MTX-induced gastrointest-
inal mucositis.
Methods
Ethical statement and husbandry specifications
All experiments were conducted in accordance with 
the ethical guidelines approved by the Dutch de 
Centrale Commissie Dierproeven (CCD) and the 
Institutional Animal Care and Use Committee of 
the University Medical Center Groningen, 
University of Groningen (RUG), under the license 
number 15338–01. All animals were individually 
housed in conventional, open cages at the Centrale 
Dienst Profdieren (CDP; Central Animal Facility) at 
the University Medical Center Groningen. Rats were 
housed under 12 h light/dark cycles with ad libitum 
access to autoclaved AIN93 G rodent chow (unless 
fasting) and sterile water. Sawdust bedding was pro-
vided in all cases as well as a toilet roll for enrich-
ment. All cages were randomly arranged across racks 
to prevent potential bias.
Preclinical model of MTX-induced GI-M and fasting 
conditions
The impact of fasting on MTX-induced GI-M was 
assessed using a validated preclinical model as 
previously described.13,14 Briefly, male Wistar rats 
(150–180 g, N = 9/group) were treated with a single 
dose of MTX (45 mg/kg, 50 mg/ml; obtained from 
Pharmachemie Holding B.V. The Netherlands) or 
a volume-equivalent dose of 0.9% NaOH adminis-
tered intravenously via the penile vein under anes-
thetic (3% isoflurane) on d 0. Rats randomized to the 
acute fasting groups were given ad libitum access to 
water; however, all food was removed for 48 h prior 
to MTX treatment. Rats were single housed to enable 
accurate fecal collection and assessment of dietary 
intake. Food and water intake were measured daily 
by manually weighing the contents of the chow hop-
per and water bottle. During the experimental period, 
HRW was responsible for maintaining animal water 
and chow eliminating the possibility of animal care-
takers to change water bottles or refresh chow.
Acute fasting was performed in age- and weight- 
matched groups. Rats were sacrificed 10 d post- 
MTX treatment via isoflurane anesthesia, cardiac 
puncture and cervical dislocation. An exploratory 
cohort of animals (N = 3 age-matched fasted, N = 3 
fed) were sacrificed on d 0 to evaluate the impact of 
acute fasting on intestinal architecture. At sacrifice, 
the intestine was resected, flushed with ice-cold 1 
X phosphate-buffered saline (PBS, pH 7.4) and was 
drop-fixed in 10% neutral-buffered formalin.
Plasma citrulline
The primary outcome of the study was plasma citrul-
line, an indicator of small intestinal enterocyte mass 
and a validated biomarker of small intestinal GI-M.15 
Repeated blood samples (75 μl) were collected from 
the tail vein into EDTA-treated hematocrit capillary 
tubes on d −2 (baseline), 0 (day of MTX), 2, 4, 6 and 
10. Citrulline was determined in 30 μl of plasma 
(isolated from whole blood via centrifugation at 
4000 g for 10 min) using automated ion-exchange 
column chromatography as previously described.16 
The change in plasma citrulline from d −2 to 0 was 
used to determine the impact of acute fasting on 
epithelial proliferation. Citrulline analysis from 
d 0–10 was used as a biomarker of GI-M.
Body composition
To determine the impact of acute fasting on body 
composition, rats were weighed daily from the 
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initiation day of fasting to d 10. On d −2 (baseline) 
and d 0, body composition was also assessed using 
the Bruker MiniSpec LF90 as per manufacturer’s 
guidelines.
Histology and immunohistochemistry
In a pilot cohort of exploratory male rats (N = 3 fed, 
N = 3 fasted), routine hematoxylin and eosin 
(H&E) staining was performed to evaluate intest-
inal architecture. Briefly, drop-fixed jejunal tissue 
was processed and embedded into paraffin wax. 
Four-micrometer sections were cut on a rotary 
microtome and mounted onto glass Superfrost® 
slides. H&E staining was performed as per routine 
protocols and slides were scanned using the 
Hamamatsu Photonics Digital Slide Scanner 
(NanoZoomer S60). Images were evaluated using 
the NDP.view2 software. Villus height and crypt 
depth were measured using annotation tools in 
NDP.view2. Ten well-oriented crypts/villi were 
measured per slide and an average calculated per 
animal.
To validate plasma citrulline as a marker of 
epithelial proliferation, we also evaluated the pro-
liferative capacity of the small intestinal post- 
fasting using Ki67 immunostaining. Briefly, 4 μm 
sections of jejunum were cut on a rotary microtome 
and mounted onto kp+ slides. After drying, sec-
tions were dewaxed in xylene and rehydrated 
through graded ethanol. Antigen retrieval was per-
formed using 800 ml of pre-heated 10 mM citrate 
buffer (pH 6.0). Slides were immersed and micro-
waved for 15 min before being cooled for 30 min at 
room temperature. Endogenous peroxidase activity 
was quenched with 1% H2O2 in methanol before 
sections were blocked in 10% normal goat serum. 
Sections were incubated with the primary antibody 
(rabbit anti-Ki67 (Fisher Scientific, RM9106-s0) 
1:50 with 10% normal goat serum in 1 X PBS) 
overnight in a humid chamber at 4°C. After three 
washes in 1 X PBS/Tween20, the secondary anti-
body was applied (Vector goat anti-rabbit/biotin 
BA-1000, 1:250 with 1 X PBS) before being incu-
bated with the ABC/PO-complex (1:25 with 1 
X PBS, Vector, PK-4000). Antibody binding was 
visualized with DAB substrate and tissue was coun-
terstained in hematoxylin before being dehydrated 
and cleared in graded ethanols and xylene. Sections 
were coverslipped and scanned using the 
Hamamatsu Photonics Digital Slide Scanner 
(NanoZoomer S60). Positive Ki67 cells were 
counted per crypt side for 10 crypts per slide and 
an average calculated per animal.
Microbiota analysis
Microbiota composition was assessed using 16S 
rRNA sequencing on paired fecal samples collected 
pre- and post-fasting. DNA was extracted using the 
double bead-beater procedure from Yu and Morrison 
(2004)17 and QIAamp DNA Stool Minikit guidelines 
(Qiagen). DNA was quantified using the NanoDrop 
UV Visible Light Spectrophotometer and the V3-V4 
region amplified using polymerase chain reaction 
(PCR). Each PCR reaction contained 1 μl of 10 μM 
341 f forward primer (V3F: 5ʹaatgatacggcgaccaccga-
gatct 3ʹ), 25 μl Phire HS II Master Mix, 22 μl DNase 
free water, 1 μl of 10 μM 806r barcoded reverse primer 
and 1 μl DNA template (100 ng/μl). These were 
denatured at 98°C for 30 sec and amplified over 31 
cycles of 98°C for 5 sec, 50°C for 5 sec, 72°C for 10 sec. 
Samples were held at 72°C for 1 min and kept at 4°C 
until collection. Amplification was confirmed using 
gel electrophoresis. Size selection and fragment 
removal were performed using AMPure XP beads as 
per manufacturer’s guidelines before the final PCR 
products were normalized to 2 mM and pooled to 
form a single library which was stored at −4°C until 
sequencing.
Sequencing was performed using the MiSeq 
Benchtop Next Generation Sequencer (Illumina). 
The paired-end sequencing data received from 
Illumina software were processed by the software 
PANDAseq (version 2.5)18 and QIIME (version 
1.7.0).19 Readouts with a quality score below 0.9 
were discarded by PANDAseq to increase the qual-
ity of the sequence readouts. De novo OTU-picking 
was performed without chimera filtering with 
Greengenes (version 13.5) as a reference database. 
Data were visualized and analyzed using the Qiagen 
CLC Genomics Workbench 12 (kindly provided by 
Qiagen to Wardill HR).
Statistical analyses
All data were analyzed using GraphPad Prism v8.0. 
Data were analyzed for normality using the 
GUT MICROBES e1809332-3
D’Agostino-Pearson Normality test, and when con-
firmed were analyzed using a two-way analysis of 
variance (ANOVA). For repeated measures, data 
were analyzed using a mixed model with Geisser’s 
Greenhouse correction. For correlations, a simple 
linear regression with Pearson correlation coeffi-
cients was used to determine the strength and sig-
nificance. P < .05 was considered significant. All 
statistical analyses are described in figure legends.
Results
Acute fasting slows epithelial turnover but severely 
depletes fat stores
To evaluate the impact of acute fasting on epithelial 
proliferation, plasma citrulline was assessed pre- 
and post-fasting (Figure 1a). Plasma citrulline is 
a biomarker of small intestinal enterocyte mass 
with decreases occurring in response to slowed 
turnover or epithelial injury. Acute fasting for 
48 h caused a significant decrease in plasma citrul-
line (−25.43 ± 3.01%, ***P < .0001, Figure 1a). 
Control animals showed no significant change in 
plasma citrulline over the 48-h period. Fasting also 
caused significant weight loss (−11.79 ± 0.34%, 
***P < .0001, Figure 1b,c), and almost complete 
depletion of body fat (13.95 ± 1.98 g [baseline] to 
0.74 ± 0.44 g [after fasting], ***P < .0001, Figure 
1d). This was paired with a decrease in lean muscle 
mass (**P = .0011, Figure 1e) and body fluid 
(**P = .0003, figure 1f). Despite the change in 
body fluid, water intake did not significantly differ 
between groups during the fasting period.
Histological analysis of the jejunum indicated 
mild but significant villus blunting in the jejunum 
(567.9 ± 12.6 μm vs 470.5 ± 12.6 μm, **P = .0054, 
Figure 2a,b). No changes were seen in crypt depth 
(Figure 2c). The impact of fasting on epithelial 
turnover was confirmed with Ki67 immunostain-
ing, with a significant decrease in Ki67+ cells after 
fasting (*P = .01, Figure 2).
Acute fasting modulates the microbiota
The effect of acute fasting on microbiota composi-
tion was assessed in N = 9 fasted male rats using 16S 
rRNA sequencing. Stool samples were collected at 
baseline and after 48 h of fasting. Acute fasting 
increased microbial richness and alpha diversity, 
indicated by the number of operational taxonomic 
units (OTUs, Figure 3a) and Shannon’s index 
(Figure 3b). Significant changes were observed in 
the relative abundance of Muribaculum;g_ (Figure 
3c, **P = .0061), Lactobacillus (Figure 3d, *P = .05), 
Clostridiales (Figure 3e, **P = .0039) and 
Ruminococcus;g_ (figure 3f, ***P = .0001). Fasting 
Figure 1. Acute fasting slows epithelial turnover and induces 
significant changes in body composition. Rats were given ad 
libitum access to food and water (fed), or water only (fasted) for 
48 h. Plasma citrulline (a), body weight (B/C) and body composi-
tion (D/E/F) were assessed at baseline and following the fasting 
period. Data points shown for all rats with N = 4/group for body 
composition analysis and N = 9/group for all other analyses. Data 
were assessed using a two-way ANOVA. P < .05 was considered 
statistically significant.
Figure 2. Acute fasting induces villus atrophy and reduced 
proliferation in the jejunum. Intestinal architecture and prolifera-
tion were assessed using H&E staining and Ki67 immunohisto-
chemistry, respectively, in N = 6 animals. Fasting decreases villus 
length (**P = .0054; A/B) yet had no effect on crypt depth (c). 
The number of Ki67+ cells in the jejunum decreased following 
48-h fasting (*P = .01; D). Data shown as individual points and 
mean. All data were analyzed with an unpaired t-test, where 
P < .05 was considered significant.
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induced a compositional shift in the microbiota 
aligning with Principle Component (PCo)2 
(Figure 3g), with strong correlations observed 
between PCo2 and Muribaculum;g_ (***P = .0009, 
Figure 3h) and Bacteroidales (***P = .0002, Figure 
3h). For all statistically significant correlations with 
PCo2, please see Table 1.
The severity of MTX-induced mucositis is not 
influenced by pre-therapy fasting
We next assessed the impact of pre-therapy fasting 
on MTX-induced gastrointestinal mucositis (GI- 
M) using a validated rat model of moderate, self- 
limiting mucosal injury. Our primary outcome 
measure was plasma citrulline assessed longitudin-
ally over 10 d. It is well documented that body 
compositions, in particular body mass index 
(BMI) and surface area, are predictors of GI-M. 
Given the profound weight loss induced by acute 
fasting, and its potential as a co-founder, we eval-
uated the impact of acute fasting in age- and 
weight-matched animals (i.e. fed and fasted rats 
were comparable body weight at the time of 
MTX). Pre-therapy fasting was unable to prevent 
the severity of GI-M as determined by plasma 
citrulline and body weight loss (Figure 4). Body 
weight was significantly higher in fasted animals 
Figure 3. Acute fasting promotes microbial diversity and richness and induces compositional changes in the fecal microbiota. 
Microbiota composition was assessed in fasted rats, with paired fecal samples collected pre- and post-fasting. Increased richness, 
indicted by OTUs (a), and alpha diversity (b) were observed after fasting. Significant changes in the relative abundance of Muribaculum 
(c), Lactobacillus (d), Clostridiales (e) and Ruminococcus (f) were identified. Compositional changes aligning with PCo2 were identified 
post-fasting (g), correlating with Muribaculum and Bacteroidales (h). A-F show paired results from individual animals (gray hashed 
lines), with the mean depicted by a solid black line. A-F were analyzed using a paired t-test where P < .05 was significant. A simple 
linear regression with Pearson correlation coefficients were used in H to determine strength and significance.
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in the first 3-d post-MTX treatment (Figure 4a, 
**P = .002, ***P = .0002, *P = .023). Food intake 
was also increased in fasted rats on the first day 
following MTX treatment (***P < .0001, Figure 4b). 
Despite this initial effect, body weight in peak GI-M 
(D 4) did not differ between fed and fasted animals. 
Similarly, the severity of the mucosal injury was 
unchanged throughout the time course of MTX- 
induced GI-M (Figure 4c).
Discussion
Methotrexate (MTX)-induced mucositis remains 
a significant and unmet need that is only set to 
Table 1. Taxonomic classifications significantly correlated with PCo2.
r P R2
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__;g__ 0.7617 0.0002 0.5802
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__ −0.7626 0.0002 0.5815
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__[Odoribacteraceae];g__Odoribacter 0.7527 0.0003 0.5666
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;g__Lactococcus −0.7521 0.0003 0.5656
k__Bacteria;p__Firmicutes;c__Bacilli;Other;Other;Other −0.7225 0.0007 0.5219
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__S24-7;g__ −0.7143 0.0009 0.5102
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;Other;Other −0.7106 0.0009 0.505
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;Other −0.6957 0.0013 0.484
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Ruminococcaceae;g__ 0.6835 0.0018 0.4672
k__Bacteria;p__Firmicutes;Other;Other;Other;Other −0.6669 0.0025 0.4448
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;Other −0.6065 0.0076 0.3678
k__Bacteria;p__Firmicutes;c__Bacilli;o__Turicibacterales;f__Turicibacteraceae;g__Turicibacter −0.5905 0.0099 0.3487
k__Bacteria;p__Firmicutes;c__Clostridia;Other;Other;Other −0.5709 0.0133 0.3259
k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria;o__Desulfovibrionales;f__Desulfovibrionaceae;g__Bilophila 0.5298 0.0238 0.2806
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Actinomycetales;f__Micrococcaceae;g__Rothia −0.5258 0.025 0.2765
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Lactobacillaceae;Other −0.5188 0.0274 0.2692
k__Bacteria;p__Firmicutes;c__Erysipelotrichi;o__Erysipelotrichales;f__Erysipelotrichaceae;g__Allobaculum 0.513 0.0295 0.2632
k__Bacteria;p__Proteobacteria;c__Deltaproteobacteria;o__Desulfovibrionales;f__Desulfovibrionaceae;g__Desulfovibrio −0.512 0.0299 0.2621
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Ruminococcaceae;Other 0.5098 0.0307 0.2599
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Lachnospiraceae;g__Dorea 0.5009 0.0342 0.2509
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Actinomycetales;f__Micrococcaceae;Other −0.4914 0.0384 0.2414
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Carnobacteriaceae;g__Granulicatella −0.4886 0.0397 0.2387
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;Other;Other 0.4874 0.0402 0.2376
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__ 0.4848 0.0414 0.235
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__[Odoribacteraceae];g__Butyricimonas 0.4744 0.0467 0.2251
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Clostridiaceae;g__Clostridium 0.4734 0.0472 0.2241
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Ruminococcaceae;g__Ruminococcus 0.4735 0.0472 0.2242
Figure 4. MTX-induced gastrointestinal mucositis is not influenced by acute fasting. Rats (N = 9/group) were treated with a single dose 
of MTX (45 mg/kg) and gastrointestinal mucositis determined by relative body weight (a), food intake (b) and plasma citrulline (c). 
Significant increases in relative body weight were identified in age- and weight-matched rats following fasting, however this did not 
affect body weight during peak mucositis (d 4) or the degree of mucosal injury indicated by citrulline. Data are shown as mean±SEM 
and were analyzed using a mixed-effects model with Geisser-Greenhouse correction. P < .05 was considered significant.
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grow as the number of cancer diagnoses increase. 
Given the increasing recognition of its contribution 
to deadly treatment complications20-22 and late effects 
in survivors of childhood cancer,23 efforts to prevent 
acute mucosal injury are paramount. Here, we report 
microbial benefits following a clinically feasible fast-
ing schedule, with paralleled decreases in epithelial 
proliferation. While encouraging, pre-therapy fasting 
for 48 h also caused detrimental effects on body 
composition and was unable to mitigate MTX- 
induced GI-M in a validated preclinical model.
Acute fasting has a number of benefits when 
compared to dietary restriction, namely its safety 
and feasibility in a clinical oncology setting, which 
has already been confirmed.24 When considering 
the challenges in scaling up a 2-week dietary 
restriction schedule in mice to humans, methods 
that exploit or build upon the insight gained from 
Tang et al., (2020) are critically valuable, particu-
larly given the magnitude of protection achieved by 
dietary restriction in a lethal model of MTX toxi-
city. Previous research has shown short-term fast-
ing (24 and 48 h) is able to protect against a lethal 
dose of etoposide;25,26 however, the mechanisms 
responsible were not addressed in detail. 
Surprisingly, despite mice losing over 20% of their 
body weight following fasting, survival was signifi-
cantly higher compared to ad libitum fed controls 
and did not compromise the anti-tumor efficacy of 
etoposide. These findings challenge our conclusion 
that despite the observed benefits of acute fasting 
on the microbiota and epithelial turnover, the dras-
tic changes in body weight, and in particular fat 
stores, mask these protective mechanisms. In line 
with findings reported by Raffaghello et al., (2008), 
fasted rats in the current study did recover to their 
pre-fast body weight very rapidly and, in fact, were 
significantly heavier than their fed counterparts on 
d 1, 2, 3 post-MTX. However, likely due to the long 
lag time of MTX, this was not maintained, and the 
degree of mucosal injury (determined by citrulline) 
was unchanged. This highlights the importance of 
using an objective biomarker of mucosal injury in 
addition to translatable endpoints (e.g. body 
weight) to provide clear insight into the degree of 
mucositis. It also highlights a limitation of our 
study, with only direct mucosal injury (citrulline) 
and body weight assessed in our model, both of 
which are affected by fasting. As such, the impact 
of fasting on unconfounded inflammatory markers 
of GI-M is unclear.
In an attempt to avoid the confounding impact on 
body weight (induced by fasting) at the time of MTX 
treatment, we also assessed the efficacy of fasting in 
a weight-matched cohort. Fasting in age-matched 
rats results in a considerable discrepancy in body 
weight at d 0 (time of MTX administration). 
Experience in our group suggests that, despite body 
weight-dependent dosing, reduced body weight at 
the time of MTX can worsen toxicity outcomes, 
aligning with low body mass index as a predictor of 
mucositis.27 Weight-matched rats were allowed to 
gain additional weight during acclimatization, to 
ensure that they were a comparable weight to control 
(fed) rats after 48 h of fasting. Contrary to our 
hypothesis, this did not affect the ability of pre- 
therapy fasting to prevent MTX-induced GI-M, indi-
cating that it is more likely that the lack of fat stores 
masks the protective cellular and microbial mechan-
isms induced by fasting. Despite the contradictory 
findings to those published by Tang et al., (2020) and 
Raffaghello et al., (2008), there are a number of 
differences that must be acknowledged. Firstly, 
both studies reporting positive effects of fasting/diet-
ary modulation used lethal doses of chemotherapy 
administered to mice. In contrast, we used a model 
of moderate, self-limiting mucosal injury that is clo-
ser to clinical treatment settings. As such, the 
mechanisms responsible for promoting survival 
may differ from those that govern mucosal injury. 
Similarly, while Raffaghello et al., (2008) report on 
etoposide which has a different mechanism and 
kinetic of cytotoxicity. Likewise, the model of MTX 
administration used by Tang et al. differs from our 
protocol (intraperitoneal administration). While 
common in preclinical practice, intraperitoneal 
administration does not align with clinical adminis-
tration of MTX, and as such, the translatability of our 
results (where MTX is administered intravenously) 
is arguably stronger.
Mechanistically, however, the insight gained from 
Tang et al., (2020) is of interest, with antibiotic 
depletion of the microbiota-exacerbating MTX- 
mortality. This aligns with the increasing recognition 
of how the microbiota may regulate anti-cancer effi-
cacy and toxicity.7,28 While the exact microbial 
changes induced by dietary restriction and fasting 
differ, both are associated with “beneficial” or 
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“protective” changes in the microbiota (i.e. increased 
diversity/richness), emphasizing the importance of 
understanding how host–microbe interactions can 
be best exploited to optimize the outcomes of cancer 
therapy and minimize toxicity. However, a major 
difference in the microbial changes observed 
between the two studies was the abundance of 
Lactobacillus, with Tang et al., (2020) reporting 
a significant increase following DR (prior to MTX), 
which correlated with survival outcomes. This con-
trasts our finding of decreased Lactobacillus follow-
ing acute fasting and may explain the differences 
observed in study outcomes. We suggest that unlike 
DR, acute fasting entirely depletes protein and sugar 
provision for resident microbes (including 
Lactobacillus) that rely on dietary sources of 
nutrition.29 This is in contrast to microbes that 
increased following acute fasting (e.g. 
Ruminococcus) that primarily utilize endogenous/ 
host nutrient sources such as mucin.30,31 Despite 
these discrepancies, it is clear that manipulating the 
microbiota in a manner that does not detrimentally 
affect body composition is likely to be a fundamental 
step in better managing the complications of cancer 
treatment. It would be of particular interest if novel 
approaches could also target epithelial proliferation 
to decrease the sensitivity of intestinal stem cells to 
cytotoxic injury. Whether this is achieved directly 
(i.e. through different fasting regimens) or indirectly 
(i.e. via the microbiota) remains to be answered.
In summary, our study highlights that a clinically 
feasible schedule of acute fasting is able to induce 
“preferable” changes in the microbiota while 
decreasing the proliferative capacity of the intest-
inal mucosa. Whilst aligning with findings from 
other fasting and dietary restriction schedules, our 
intervention was unable to protect against MTX- 
induced GI-M, highlighting the challenges in mod-
ulating host–microbe interactions in 
a translationally meaningful manner. Future stu-
dies should focus on identifying a dietary protocol 
that is safe and feasible, and investigate schedules of 
fasting that provide greater protection in the acute 
phases of injury.
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